| Phase 13 trials |
|
Phase 1
|
NCT07169630 |
Jul 2026 → Apr 2029 expected |
Alzheimer disease, cognitive impairment with or without cerebellar ataxia |
National Institute of Mental Health (NIMH) |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06790394 |
Oct 2025 → Sep 2026 expected |
amyloidosis |
Lantheus Holdings, Inc. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT03706261 |
Mar 2019 → Jul 2023 |
Alzheimer disease |
Adam Brickman |
Completed
|
No outcome recorded
|
| Phase 23 trials |
|
Phase 2
|
NCT04840979 |
May 2021 → Dec 2026 expected |
Alzheimer disease |
Columbia University |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT03057938 |
Jul 2020 → Jan 2022 |
subjective cognitive decline |
Fundacion Clinic per a la Recerca Biomédica |
Withdrawn
|
No outcome recorded
|
|
Phase 2
|
NCT02831283 |
Jun 2016 → Dec 2022 |
Alzheimer disease |
Patrick Lao |
Completed
|
No outcome recorded
|
| Phase 31 trial |
|
Phase 3
|
NCT05184088 |
Jan 2023 → Apr 2026 |
AL amyloidosis |
Lantheus Holdings, Inc. |
Completed
|
No outcome recorded
|
| Phase 41 trial |
|
Phase 4
|
NCT02681172 |
Oct 2015 → Sep 2016 |
Alzheimer disease |
Piramal Imaging Limited |
Completed
|
No outcome recorded
|
| Phase not applicable5 trials |
| — |
NCT07624760 |
Oct 2026 → May 2028 expected |
AL amyloidosis, monoclonal gammopathy of uncertain significance, plasma cell myeloma |
University of Zurich |
Not yet recruiting
|
No outcome recorded
|
| — |
NCT04392960 |
Jul 2020 → Jun 2025 |
AL amyloidosis |
Fondazione IRCCS Policlinico San Matteo di Pavia |
Completed
|
No outcome recorded
|
| — |
NCT03616496 |
Jun 2019 → Jan 2025 |
amyloidosis |
Central Hospital, Nancy, France |
Completed
|
No outcome recorded
|
| — |
NCT03779815 |
Aug 2018 → Feb 2019 |
plasma cell myeloma |
Ulsan University Hospital |
Completed
|
No outcome recorded
|
| — |
NCT01222351 |
Dec 2010 → Oct 2014 |
Alzheimer disease 2 |
New York State Psychiatric Institute |
Completed
|
No outcome recorded
|